VolitionRX (NYSEAMERICAN:VNRX) Releases Quarterly Earnings Results, Misses Estimates By $0.27 EPS

VolitionRX (NYSEAMERICAN:VNRX) announced its quarterly earnings results on Thursday. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.27), FiscalAI reports. The firm had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.52 million.

VolitionRX Price Performance

NYSEAMERICAN VNRX traded down $0.16 on Thursday, reaching $2.20. The company had a trading volume of 103,794 shares, compared to its average volume of 262,034. The firm has a market cap of $17.80 million, a price-to-earnings ratio of -0.50 and a beta of 1.03. VolitionRX has a fifty-two week low of $2.01 and a fifty-two week high of $18.80. The business has a 50 day moving average of $3.35 and a two-hundred day moving average of $4.98.

Institutional Trading of VolitionRX

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in VolitionRX in the fourth quarter valued at $28,000. Virtu Financial LLC increased its holdings in VolitionRX by 166.6% in the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 67,848 shares during the period. Squarepoint Ops LLC bought a new stake in VolitionRX during the fourth quarter valued at $34,000. Northwestern Mutual Wealth Management Co. bought a new stake in VolitionRX during the second quarter valued at $52,000. Finally, Citadel Advisors LLC boosted its position in VolitionRX by 70.1% during the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after acquiring an additional 135,775 shares during the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

VNRX has been the subject of several research analyst reports. Citigroup downgraded shares of VolitionRX to a “hold” rating in a report on Monday, April 20th. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a report on Monday, April 20th. Finally, HC Wainwright lowered their price target on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.67.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.